Zeus Releases StreamLiner OTW

By extruding over wire, Zeus has produced the desired combination of wall thickness, flexibility, and strength. Zeus’ StreamLiner OTW products allow medical device manufacturers to develop safer, smoother and stronger catheters that can navigate deeper into a patient’s vasculature.

With the release of StreamLiner OTW, Zeus offers medical device manufacturers several advantages:

  • A product with a similar wall thickness and the flexibility of film cast PTFE liners but with greater strength.
  • Shorter lead times to speed time-to-market and reduce operational costs. Zeus’ in-house wire drawing capabilities increase wire availability, reduce turnaround times and shorten delivery schedules.
  • Simplified production processes. Zeus supplies straight, cut-to-length liners that allow you to take the product from packaging to production and eliminate multiple timely processes.

Specific catheter applications for the StreamLiner OTW family include occlusion balloon catheters, microcatheters, mechanical and aspiration thrombectomy catheters, intermediate catheters, guiding catheters with and without balloons, and support catheters.

COMMENTS

“Zeus continues to lead with its technological innovations in PTFE liners. Using a state-of-the-art process, our new StreamLiner OTW lineup opens the doors to new possibilities for catheter manufacturers. Currently, no other polymer solution provider can supply an extruded PTFE liner with comparable wall thickness, flexibility and strength. Zeus is the only company in the market capable of delivering flexible PTFE liners extruded over wire with the lowest wall thickness.” Bob Chaney, Senior Vice President, Global Sales & Marketing, Zeus Industrial Products, Inc.

“StreamLiner OTW bridges the gap between film cast liners and free extruded liners by providing extremely thin walls, flexibility, and strength. These features enable more catheter design options, which ultimately translates to better tractability, deliverability and overall performance – all without compromising patient safety.” Matt Allen, Senior Product Line Manager, Zeus Industrial Products, Inc.

QUICK FACTS

  • Zeus has launched StreamLiner OTW, a new product lineup within its StreamLiner™ family of thin, extruded PTFE catheter liners.
  • StreamLiner OTW uses a proprietary process that extrudes PTFE liners over-the-wire in a range of sizes with comparable wall thickness and flexibility to film cast tubing, but with greater strength.
  • The new product lineup offers nominal wall thicknesses as low as 0.0004″.
  • The new liners are provided in discrete straight lengths over silver-plated copper.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version